Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

Disease characteristics, age, and geography are among the main factors that shape first-line treatment patterns in patients ...

The Alliance for Clinical Trials in Oncology has launched a new clinical trial for adults who need first-line therapy for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The ...

Statin use in CLL/SLL patients treated with ibrutinib reduced cancer-related death risk by 61% and improved survival outcomes. The study found no significant increase in severe side effects with ...

When Nathan was diagnosed with chronic lymphocytic leukemia (CLL) at just 45 years old, his world turned upside down overnight. As a military veteran and ER nurse, he was no stranger to facing ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Matthew S. Davids, MD, said data from the BRUIN-313 trial supports front-line approval ...

Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...

What Is It, and Why Does It Matter? The FDA has approved a new combination treatment for adults with certain cancers of the blood and lymphatic system. The targeted regimen combines Calquence ...

Eli Lilly (LLY) announced on Tuesday that its Bruton tyrosine kinase inhibitor Jaypirca (pirtobrutinib) reached the main goal in a Phase 3 trial for certain newly diagnosed patients with chronic ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced its new partnership with CLL Society, the ...

Please provide your email address to receive an email when new articles are posted on . In the BRUIN CLL-313 trial, researchers compared pirtobrutinib (Jaypirca, Eli Lilly & Co.) vs. bendamustine plus ...

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center ...